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Over the past decade, the excited delirium syndrome (ExDS) has raised continued
controversy regarding the cause and manner of death of some highly agitated persons
held in police custody, restrained or incapacitated by electrical devices. At autopsy,
medical examiners have difficulty in identifying an anatomic cause of death, but
frequently cite psychostimulant intoxication as a contributing factor. The characteristic
symptoms of ExDS include bizarre and aggressive behavior, shouting, paranoia, panic,
violence toward others, unexpected physical strength, and hyperthermia. Throughout
the United States and Canada, these cases are most frequently associated with cocaine,
methamphetamine, and designer cathinone abuse. Acute exhaustive mania and sudden
death presents with behavioral symptoms that are identical to what is described for
ExDS in psychostimulant abusers. Bell’s mania or acute exhaustive mania was first
described in the 1850’s by American psychiatrist Luther Bell in institutionalized psychiatric
patients. This rare disorder of violent mania, elevated body temperature and autonomic
collapse continued to be described by others in the psychiatric literature, but with
different names until the first cases of ExDS were seen at the beginning of the cocaine
epidemic by medical examiners. The neurochemical pathology examination of brain
tissues after death revealed a loss of dopamine transporter regulation together with
increases in heat shock protein 70 (hsp70) expression as a biomarker of hyperthermia.
The similarity in the behavioral symptoms between extremely agitated psychostimulant
abusers and unmedicated psychiatric patients suggests that a genetic disorder that leads
to dysregulated central dopamine transporter function could be a precipitating cause of
the acute delirium and sudden death. While the precise cause and mechanism of lethality
remains controversial, the likely whys and wherefores of sudden death of ExDS victims
are seen to be “biological,” since excessive dopamine in the brain triggers the manic
excitement and delirium, which unabated, culminates in a loss of autonomic function
that progresses to cardiorespiratory collapse.
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INSET
HenryMaudsleyMD described AcuteMania and AcuteManiacal
Delirium in 1867 in his “Physiology and Pathology of the Mind,”
which best illustrates the view discussed in this article. He
suggests that persons in an agitated state of acute mania benefit
from “abundant exercise in the open air” while “such a practice
would be most unscientific in acute delirium, and very likely to
be followed by fatal consequences”. He further states “it would be
better to place a patient suffering from such acute degeneration of
cerebral function entirely in seclusion” rather “than to aggravate
his disorder by forced exercise and mischievous struggles with
attendants”. Medico-legal reports more than a hundred and fifty
years after Maudsley and Luther Bell find the prognosis is never
very favorable for individuals at risk for excited delirium.
HISTORICAL DESCRIPTIONS AND CASE
REPORTS
Psychiatrists in the United Kingdom, France and America were
the first to provide clinical descriptions and case reports of
persons in states of acute exhaustive mania and delirium. In
the 1800s, Dr. Luther Bell, psychiatrist at the McLean Asylum
for the Insane in Massachusetts described a clinical condition
with a 75 percent mortality rate. “Bell’s mania” or acute
exhaustive mania was characterized by delusions, hallucinations,
hyperactivity, and frequent fevers. The descriptions although
similar to the psychotic features of paranoid schizophrenics (e.g.,
hallucinations and delusions) revealed a more extreme condition
of generalized severe disorganization of behavior, including
hyperactive arousal, altered sleep-wake cycle, and elevated
core body temperature. Calmeil’s report of an uncommon,
but life threating psychosis with extreme hyperactivity and
mounting fear fading to stuperous exhaustion in 1832 was
followed by Maudleys’ description of the same disorder in 1867
(inset). Agitated delirium signs and symptoms were reported
in hyperactive or mixed forms of the disorder throughout the
pre-neuroleptic era of psychiatry (Kraines, 1934; Stauder, 1934;
Larson, 1939).
In 1934, Stauder published detailed observations of 27 cases,
which became the definitive description of a syndrome that he
termed lethal catatonia (Stauder, 1934). The cases were mostly
young people, in the age range of 18–26 years, who had no
significant premorbid psychological or physical disturbances.
Stauder observed the acute onset of a severe form of psychomotor
agitation that he called “elementary catatonic excitement.”
Various degrees of clouding of consciousness and a strong
tendency toward violent and self-destructive acts also were
present. Although different nomenclature was used to describe a
psychotic exhaustion syndrome, fatal cases of a life-threatening
febrile neuropsychiatric disorder were widely recognized and
reported by clinicians before modern psychiatric treatments
became available (Shulack, 1946). The authors of these published
reports found it remarkable that autopsies of these patients failed
to reveal any clues to etiology or the cause of death, other than
exhaustion.
Between 1954 and 1975, the advent of the neuroleptic drugs
like Thorazine transformed psychiatric practice and reduced
the incidence of exhaustive mania in institutionalized and
unmedicated patients. However, the cocaine epidemic of the
1980’s lead to a series of case reports describing sudden death
in cocaine abusers with an extreme behavioral malady similar to
what had been reported by Bell and others 150 years earlier. The
agitated cocaine delirium deaths were associated with cocaine
abuse and their appearance coincided with the introduction
of cocaine into the United States (Fishbain and Wetli, 1981;
Wetli, 1987). The trans-shipment of cocaine to South Florida
through the Bahamian corridor and the increased incidence of
cocaine-related medical emergency room admissions and drug
related deaths placed Medical Examiners in Miami-Dade at the
forefront of a new wave of cocaine-related excited delirium
deaths.
Wetli and Fishbain (1985) described a case series of psychosis
and sudden death in cocaine abusers, which was the first report
of drug-related excited delirium (Table 1). The deaths occurred
mostly in young cocaine intoxicated males, who exhibited
extreme hyperactivity and violent behavior, hyperthermia and
sudden cardiorespiratory collapse. Because these patients always
presented with agitated and bizarre behavior, law enforcement
was often called to the scene. The typical course was that
after police restrained the individual, they died unexpectedly
and suddenly following the use of various force methods,
including maximal restraints, baton strikes, or use of noxious
chemical “pepper” sprays (Wetli, 1987; Ross, 1998; Stratton
et al., 2001). Medical examiner review of these cases did
not reveal a definite anatomic cause of death, although
drug overdose, trauma, and underlying cardiac disease were
excluded (Wetli, 1987; Ruttenber et al., 1997; Stephens et al.,
2004).
TABLE 1 | Historical descriptions and terminology of excited delirium
syndrome.
Author and year Nomenclature Clinical description
Calmeil, 1832 Delirious mania Rare, life-threatening psychosis
extreme hyperactivity, mounting fear,
stuporous exhaustion
Bell, 1849 Bell’s mania Sudden onset of hyperactive arousal,
confusion, transient hallucinations,
core body temperature dysregulation,
75% mortality rate
Maudsley, 1867 Acute maniacal
delirium
Violent mania, rapid pulse, constant
motion, elevated temperature of skin,
complete exhaustion
Stauder, 1934 Lethal catatonia Intense motor excitement, violent,
suicide attempts, intermittent rigidity,
incoherent speech, bizarre delusions;
fever (43.3◦C), cardiovascular
collapse
Wetli and Fishbain,
1985
Excited delirium Agitation motor excitement, super
human strength, paranoia, mounting
fear, hyperthermia, cardiorespiratory
collapse, cocaine intoxication, no
anatomic cause of death
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FATAL COCAINE DELIRIUM AS A VARIANT
OF THE NEUROLEPTIC MALIGNANT
SYNDROME
Neuroleptic malignant syndrome (NMS) is a rare, life-
threatening idiosyncratic reaction to antipsychotic drugs
characterized by fever, altered mental status, muscle rigidity, and
autonomic dysfunction (Levenson, 1985; Weinberger and Kelly,
1977; Berman, 2011). The hallmark symptoms of NMS include
hyperpyrexia and muscular rigidity, while the cocaine-associated
syndrome is atypical in having minimal rigidity. Based on these
similarities, Kosten and Kleber (1988) proposed that cocaine-
induced excited delirium should be considered a dopamine
agonist variant of NMS. Wetli (2005) proposed that NMS
might be an attenuated form of acute exhaustive mania/excited
delirium. These observations lead him to hypothesize that there
may be three related syndromes: (1) acute exhaustive mania, as
described by Bell in psychiatric patients, (2), excited delirium,
due to psychostimulants; and (3) the attenuated variant—NMS
(for review, Wetli, 2005).
Delirious mania and malignant catatonia both have
non-malignant and malignant clinical features with early,
non-malignant symptoms responding to neuroleptics, while
patients who pass over into the malignant phase require sedation
by benzodiazepines (Mann et al., 2013). Although NMS is a rare,
life-threatening idiosyncratic reaction associated with virtually
all neuroleptics, including the newer atypical antipsychotics
(e.g., dopamine blockers), the condition is linked also to the
use of indirect and direct-acting dopamine agonists. The abrupt
cessation or reduction in dose of dopaminergic agonists, such as
levodopa, pergolide, and amantadine in Parkinson’s disease may
precipitate NMS in vulnerable patients (Ito et al., 2001; Reimer
et al., 2002). Interestingly, the akinetic crisis of Parkinson’s
disease is associated with a severe loss of striatal dopamine
transporter function (Kasssinen et al., 2014). This rare condition
is a life-threatening complication of Parkinson’s disease, with an
estimated annual incidence of 0.3% and death rate of 15%, that
is associated with hyperthermia, dysautonomia, and increased
serum muscle enzymes (Takubo et al., 2003; Onofrj et al.,
2009). The clinical picture is similar to that of NMS and has
been termed as the malignant syndrome of parkinsonism-
hyperpyrexia. The condition is not related to disease stage or
medication dosage, but one of the main features is that, the
akinetic crisis appears to be long lasting (on average 11 days)
and the dopamine system is transiently blocked from treatments,
which would usually give patients rapid motor benefit. To date,
none of the theories put forth as the underlying cause of the
NMS related syndrome in Parkinson’s disease have been able
to explain why only a small fraction of patients exposed to
dopaminergic agonists develop the condition, although state
(dopaminergic drugs) and trait (genetic) vulnerabilities are likely
risk factors.
Hypothalamic dopamine antagonism leads to the elevated
set point for thermoregulation and the myotoxicity associated
with malignant hyperthermia. Sympathoadrenal hyperactivity
and the loss of hierarchical integration and homeostatic
control may constitute important risk factors for NMS and its
associated variants. Gurrera (1999) advanced this hypothesis,
suggesting that sympathetic nervous system hyperactivity should
be viewed as primary in the etiology of NMS. The sympathetic
nervous system mediates the hypothalamic coordination of
thermoregulatory activity and is a regulator of muscle tone and
thermogenesis. The sympathetic nervous system’s latent capacity
for autonomous activity is expressed when tonic inhibitory inputs
from higher central nervous system dopaminergic centers are
disrupted. The predominant sources of spinal dopamine are
the descending fibers projecting from the dopaminergic A10
and A11 cell groups of the posterior hypothalamus (Skagerberg
and Lindvall, 1985; Qu et al., 2006). These tonic inhibitory
inputs relay to preganglionic sympathetic neurons by way of the
dopaminergic hypothalamospinal tracts.
A predisposition to more extreme sympathetic nervous
system activation and/or dysfunction in response to emotional or
psychological stress may be an underlying state vulnerability for
NMS, as well as, for the ExDS associated with psychostimulant
abuse. State variables like the acute psychic stress reported
originally in Bell’s mania when coupled with a loss of
presynaptic dopaminergic transporter function may lead to
extremely elevated concentrations of synaptic dopamine, and the
emergence of related clinical syndromes.
EXCITED DELIRIUM IS A SYNDROMAL
DISORDER OF DYSREGULATED
DOPAMINE
A syndrome is the association of several clinically recognizable
features, signs, symptoms, or characteristics that often occur
together, so that the presence of one feature alerts to the
presence of the others. Most recognize that the condition of
excited delirium represents a syndromal disorder rather than a
specific disease. What has not been emphasized in the literature
is that various organic brain disorders, as well as functional
psychiatric conditions and psychostimulant abuse, contribute
to the expression of a CNS disorder with high fatality rates
that share a common underlying neurochemical dysregulation of
central dopamine homeostasis.
Persons at risk for excited delirium are most likely at the
extreme end of the neuropsychiatric continuum of several DSM-
IV recognized disorders, including delirium induced by a drug,
manic excitement, and psychomotor agitation (Vilke et al.,
2012). Those at risk for excited delirium and sudden death
include people who are withdrawing from or non-compliant with
psychotropic drugs, substance abusers suffering from reward
deficiency syndrome or alcoholics in withdrawal, and persons
suffering from acute manic episodes that may be triggered or
worsened by sleep deprivation.
The clinical description of excited delirium includes reports
of increasing excitement with wild agitation and violent, often
destructive behavior that can last for hours to days. The forensic
pathology descriptions suggest that the disorder can wax and
wane in severity over time with rigidity or stupor alternating
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with excitement (Wetli, 2005; DiMaio and DiMaio, 2006). These
progress to increasing and possible fluctuations of fever and
persistent autonomic instability with rapid and weak pulse
and hypotension. Cocaine delirium shares clinical similarity to
the acute onset of excitement, grandiosity, emotional lability,
delusions, and insomnia associated with emergence of mania,
and the disorientation and altered consciousness characteristic of
delirium. Psychostimulant intoxication, drug withdrawal states,
and undiagnosed mania and bipolar affective disorder are the
most commonly reported antecedents (Wetli, 2005; Mash et al.,
2009; Vilke et al., 2012).
PATHOPHYSIOLOGY AND
NEUROCHEMICAL TRIGGERS
Transmission of reward signals is a function of dopamine,
a neurotransmitter known to be involved in the mechanism
of psychosis. The symptoms of psychosis and mania are
both related to dopaminergic hyperactivity in brain circuits
implicated in neuropsychiatric disorders (Cipriani et al.,
2011). In psychosis, post-synaptic receptor sensitization causes
dysfunctional neural processing, leading to the development
of delusional symptoms. This understanding fits well with
the traditional hyperdopaminergic hypothesis of psychosis and
schizophrenia. The hyperdopaminergia and disordered signaling
in dopamine target regions of the brain also serves as a model
for mania, since dopaminergic blocking drugs are effective in
alleviating mania and psychosis.
Mania is the cardinal feature and a core symptom of bipolar
disorder. PET scans in medicated, manic patients show abnormal
brain activation in dorsal anterior cingulate, frontal polar,
and right inferior frontal cortical regions (Rubinsztein et al.,
2001). The increase in task-related anterior cingulate activation
was positively correlated in this study with the severity of
manic symptoms. Anterior cingulate cortex activation may be
related to increased nucleus accumbens dopamine signaling,
which leads to cortical and subcortical hyperactivity in mania
(Perry et al., 2001). Genetic linkage studies have suggested an
association of the dopamine transporter gene (Kelsoe et al., 1996;
Greenwood et al., 2001, 2006) and lower levels of transporter
protein expression in patients with bipolar affective disorder
(Amsterdam and Newberg, 2007).
Cocaine and methamphetamine increase extracellular
dopamine and produce behavioral effects similar to mania
(Silverstone et al., 1983). Drug sensitization occurs in drug
addiction, and is defined as an increased effect of a drug
following repeated doses (the opposite of drug tolerance). Such
sensitization involves increased brain mesolimbic dopamine
transmission, as well as altered protein expression within
mesolimbic dopamine neurons. Repeated treatment with
psychostimulants leads to sensitization or reverse tolerance in
animal models (Post and Rose, 1976; Hooks et al., 1994; Pierce
and Kalivas, 1997; Zapata et al., 2003) and human cocaine
abusers (Ujike and Sato, 2004; Seeman, 2011). Paranoia in the
context of cocaine abuse is common and potentially dangerous
and several lines of evidence suggest that this phenomenon may
be related to loss of function of the dopamine transporter protein
(Gelernter et al., 1994; van Dyck et al., 2005). These observations
suggest that certain dopamine transporter genotypes might
predispose to paranoia with chronic psychostimulant abuse.
The dopamine transporter undergoes neurobiological
adaptations with chronic abuse of cocaine, depending on the
duration, amount and pattern of use (e.g., binge vs. daily use).
Intermittent cocaine self-administration in rodents produces
sensitization of the stimulant effects of cocaine at the dopamine
transporter (Calipari et al., 2014) and enhanced locomotor
responsiveness or what is termed behavioral sensitization
(Kalivas and Duffy, 1993; Robinson and Berridge, 1993; Kalivas
et al., 1998). This phenomenon is not unique to cocaine; other
psychomotor stimulants, some other classes of drugs, and mental
stress induce the phenomenon of behavioral sensitization. Since
cocaine directly inhibits dopamine reuptake by binding to
the transporter, repeated cocaine administration may lead to
a reduced potency of cocaine, which leads to an elevation in
synaptic dopamine and the expression of behavioral sensitization
(Zahniser et al., 1995, 1998).
The dopamine transporter expressed in presynaptic terminals
of dopamine neurons regulates reuptake of dopamine from the
synaptic cleft and keeps extracellular dopamine concentrations
low (Amara and Kuhar, 1993; Giros and Caron, 1993; Mortensen
and Amara, 2003). The dopamine transporter is critical in
regulating the concentration of extracellular dopamine and
overall dopaminergic tone (Mash and Staley, 1996; Drevits
et al., 1999; Mash et al., 2002, 2009). By blocking the
transporter protein, cocaine allows released dopamine to persist
in the extracellular space, which prolongs dopamine receptor
stimulation (Figure 1). A decrease in dopamine transporter
numbers or function in response to cocaine leads to reduced
dopamine reuptake, elevated synaptic dopamine, and increased
dopamine signaling at postsynaptic receptors.
The syndrome of excited delirium in drug abusers
demonstrates that cocaine is the most frequent reported
illicit drug (Ruttenber et al., 1997; Mash et al., 2009; Vilke
et al., 2012). Most drug-related excited delirium victims are
chronic freebase cocaine (“crack”) abusers, usually engaged in
a “binge” pattern of drug use (Mash et al., 2002, 2009; Wetli,
2005). These persons use large amounts of “crack” cocaine or
methamphetamine often for days, which interrupts normal
sleep-wake cycles. Inhibition of dopamine transporter function
is thought to be the primary mechanism underlying cocaine’s
addictive effects (Ritz et al., 1987). Although excited delirium is
most frequently reported in cocaine abusers, psychostimulants
including, methamphetamine, MDMA, alpha-PVP, methylome,
and ephedrine have been associated with the syndrome (Mash
et al., 2009; Penders et al., 2012). These psychostimulants directly
interact with the dopamine transporter to cause a marked
increase in the levels of synaptic dopamine.
Postmortem neurochemical studies of the human brain at
autopsy demonstrate that chronic cocaine abuse leads to a
compensatory upregulation of dopamine transporter number
and function (Staley et al., 1994; Little et al., 1999; Mash et al.,
2002). In contrast, there was no compensatory upregulation
in dopamine transporter numbers in a case series of 90
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FIGURE 1 | Dysregulated dopamine transporter function in ExDS. Located on presynaptic dopamine nerve terminals, the dopamine transporter functions to
regulate the duration and intensity of synaptic dopamine signaling (left). Cocaine (red) inhibits the reuptake of dopamine by blocking the transporter protein (center).
With chronic cocaine abuse, the dopamine transporter is trafficked to the plasma membrane as a compensatory adaptation to increases in synaptic dopamine. In
ExDS victims, there is a loss of dopamine transporter regulation, which causes dopamine overflow in the synapse (right). The elevated synaptic dopamine leads to a
state of hyperdopaminergia, that is associated with the intense motor excitement, paranoia, bizarre, and often violent behavior. DAT, dopamine transporter; DA,
dopamine; D2, D2 dopamine receptor; D3, D3 dopamine receptor.
cocaine-related excited delirium and exhaustive mania victims
(Mash et al., 2009). The cocaine-related excited delirium
cases occurred in persons who had reported histories of
chronic cocaine abuse, consistent with the quantification of
benzoylecgonine in blood and cocaine and benzoylecgonine
measured in brain at autopsy (Mash et al., 2009). Mean core
body temperature among the 90 victims was 40.7◦C. Although
the majority tested positive for cocaine, four had no licit or illicit
drugs or alcohol measured in blood at autopsy. Forensic review
of these four cases reported the cause of death as acute exhaustive
mania, similar to the original description reported by Bell (1849).
All psychostimulants (e.g., cocaine, methamphetamine, and
MDMA) increase the synaptic levels of dopamine (Amara and
Kuhar, 1993; Giros and Caron, 1993), which may explain why
chronic psychostimulant abusers are more at risk for exhibiting
the behavioral symptoms associated with ExDS. A central role of
dopamine is to mediate the “salience” of environmental events
and internal representations in a dynamic process characterized
by time and stimulus-dependent neural regulation (Kapur, 2003;
Howes and Kapur, 2009). Dopamine can enhance both approach
and avoidance behaviors and trigger extreme fear (Faure et al.,
2008). In chronic cocaine abusers, there is a compensatory
upregulation in dopamine transporter function, which is an
adaptive increase to offset dopamine overflow in the synapse
(Figure 1). When this homeostatic control of synaptic dopamine
fails, it leads to a functional hyperdopaminergia, which triggers
the acute onset of delirium andmarked agitation in ExDS victims
(Staley et al., 1996; Wetli et al., 1996; Mash et al., 2002, 2009).
Rhabdomyolysis secondary to mania and cocaine excited
delirium is related to extreme physical exertion, although
increased sympathetic tone during manic states and elevated
epinephrine also play a role in its development (Manchip and
Hurel, 1995; Ruttenber et al., 1999). Ruttenber et al. (1999)
suggested that cocaine-associated rhabdomyolysis and excited
delirium are components of the same syndrome and share
the same initiating factors and pathophysiologic processes.
Both hyperthermia and hyperactivity play important roles
in the evolution of cocaine-associated rhabdomyolysis and
excited delirium. Interestingly, in NMS, the elevated risk
for hyperthermia results from disordered dopamine signaling
precipitated by chronic administration of neuroleptic drugs
(Strawn et al., 2007). The hyperthermia of neuroleptic malignant
syndrome is associated with psychomotor agitation, and
both syndromes have been related to increases in dopamine
concentrations involved in thermoregulation and neuromuscular
homeostasis (Keck et al., 1989).
Some undiagnosed psychiatric patients or those who are
neuroleptic medication non-compliant may be at increased
risk for excited delirium and sudden cardiac death. Dopamine
transporter numbers fall below the normal homeostatic range
for regulating dopamine in all cases of fatal excited delirium,
including those with no known history of drug abuse and a
negative toxicology screen at autopsy. These results suggest that
the unabated conditions, which favor the development of excited
delirium, are psychostimulant abuse, extreme mental stress or an
underlying, or perhaps undiagnosed psychiatric condition.
A final common pathway for excited delirium related
to chronic stimulant drug abuse, extreme environmental
stress or acute mania of bipolar disorder might be a
failure of the dopamine transporter to dynamically regulate
synaptic dopamine. This failure of regulation leads to a
hyperdopaminergic state, which triggers the violent behavior,
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delirium, agitation, and motor excitement. Dopamine systems
in the brain also play a role in temperature regulation (Mann
and Boger, 1978). The rise in core body temperature is most
likely induced by dopamine stimulation of D1 receptors in the
human hypothalamus which occurs because of a downregulation
in D2 mediated hypothermia (Mash, 2009). A dopamine
transporter murine model of hyperdopaminergia displays a
distinctive cardiorespiratory and thermal phenotype, providing
further support for altered dopamine transporter regulation in
excited delirium (Vincent et al., 2007). Dopamine also regulates
sleep and arousal, suggesting that there might be an inter-
relationship between thermal behavior and circadian rhythms
mediated by disrupted CNS dopamine signaling in excited
delirium.
WHEN NEUROCARDIAC SIGNALS TURN
LETHAL
Mental and emotional stress is expressed in the brain as
fluctuations in the activity of a subset of brain regions, including
the insula, cingulate cortex, and amygdala (Critchley, 2009).
These regions serve as an interface between emotional feeling
states and visceral responses of the body. The insula and cingulate
are viscerosensory cortices, which function to regulate attention
and autonomic arousal. The amygdala is important in detecting
and learning threat even in the absence of conscious awareness.
The insula and cingulate cortices and subcortical regions of the
limbic brain are heavily innervated by dopaminergic projections
from the ventral tegmental nucleus (Gaspar, 1989). These closely
connected brain regions together with the dorsal and ventral
striatum are viewed as a “salience network,” acting directly
on hypothalamic and brainstem centers to increase our bodily
arousal state through direct coupling with sympathetic and
parasympathetic efferent nuclei and feedback control loops
located in the brainstem.
The insular cortex and the infralimbic cortex are part of a
network involved in the descending control of the cardiovascular
system (for review, Cechetto, 2013). These forebrain regions
are responsible for integrating emotional and cognitive aspects
related to cardiovascular responses. Together with the autonomic
nervous system nuclei of the brainstem, these forebrain regions
regulate cardiac function and electrophysiology via direct neural
influences. Taggart et al. (2011) suggest that the roles of
mental stress and emotion in arrhythmogenesis and sudden
cardiac death are no longer confined to the realm of anecdote,
but should be viewed as contributors to the pathophysiology
of cardiac sudden death. Sympathetic arousal magnifies the
electrophysiological effects of ischemia (for review, Taggart
et al., 2011) and abnormal brain activity during seizures is
associated with abnormalities of cardiac repolarization, and peri-
ictal VT/VF in the absence of any visible cardiovascular disease
(Taggart, 2013). A centrally triggered arrhythmia is a likely cause
of sudden unexpected death in epilepsy (Surges et al., 2010), and
a similar neurocardiac mechanism could underlie the sudden
cardiac collapse in ExDS.
An emerging theme from animal models of asphyxia and
cardiac arrest supports the notion that the autonomic nervous
system is under constant surveillance by the cerebral cortex
to ensure functional integrity of vital organs (Borjigin et al.,
2013). A life-threatening crisis of the heart, with a rapid
and steep change in heart rate and cardiac output, markedly
activates and recruits the cerebral cortex to form a hierarchical
circuit of cardiac survival. When transient homeostatic feedback
from the brain to the heart is insufficient to restore cardiac
function, the brain may exhibit a sustained activation that
causes a premature and rapid death of the heart (Li et al.,
2015).
Dopamine (DA) is an immediate precursor of noradrenaline
that has stimulatory or inhibitory effects on a variety of
adrenergic receptors. Dopamine also suppresses responsiveness
to hypoxia, both in the carotid bodies and in the CNS (Huey
et al., 2000). Although the physiological relevance is not
established, one possibility is that suppression of stimulatory
responsiveness to hypoxia is a protective mechanism directed
against excessive discharge activity in the CNS respiratory
network, which can result in neuronal excitotoxicity (Richter
et al., 2000, for review Lalley, 2008). In the rat asphyxia model
of cardiac sudden death, at as early as time 0, a sevenfold
elevation in dopamine levels is measured by microdialysis
with increased 3-MT (3-methoxytyramine) and decreased
DOPAC (3,4-dihydroxyphenylacetic acid) concentrations. Since
hyperdopaminergia is a condition of ExDS, the increase in
synaptic dopamine may account for the decreased respiratory
rate caused by dysfunctional adaptations in respiratory network
rhythm.
Victims of ExDS usually die from cardiopulmonary arrest
(Takeuchi et al., 2011; Vilke et al., 2012). Sudden cardiac
death induced by a life-threatening stressor results from a
generalized sympathetic storm within the autonomic nervous
system (Samuels, 2007). Consistent with this view, exposure to
carbon dioxide leads to an immediate systemic surge of neurally
released dopamine and norepinephrine in asphyxic rats (Li et al.,
2015). Experimental brain stimulation of the left insula can
induce QT prolongation, bradycardia, and pulse-less asystole
(Oppenheimer et al., 1991; for review, Taggart, 2013), similar
to the sudden loss of vital signs with asystole reported in ExDS
victims (Vilke et al., 2012). Life-threatening stress can lead to
sudden cardiac death in people with no previous history of
abnormal heart and brain function (Samuels, 2007; Sharkey
et al., 2011). These observations suggest that autonomic toxicity
induced by central hyperdopaminergic activity in ExDS may
hasten the demise of heart function (Samuels, 2007; Li et al.,
2015).
CONCLUSIONS
Elevated synaptic dopamine when coupled with failed dopamine
transporter function leads to agitation, paranoia and violent
behaviors associated with ExDS. CNS dopamine also regulates
heart rate, respiration, and core body temperature with chemical
imbalance resulting in tachycardia, tachypnea, and hyperthermia.
Hyperthermia is a hallmark of excited delirium and a harbinger
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of death in this syndromal disorder. Victims of excited delirium
are in an extremely heightened emotional state exhibitingmarked
paranoia and mounting irrational fear. Abnormal signaling in
the brain-heart axis may be a precipitant of a sudden fatal
arrhythmia, since hyperdopaminergic signaling in the limbic
system can convert extreme emotional stress into autonomic
toxicity. The connection between the hyperdopaminergia and
chaotic signaling in higher brain autonomic regulatory centers
may explain the abrupt loss of autonomic function that leads to
sudden unexpected death in victims of the ExDS.
Excited delirium is a syndromal disorder, which is
controversial and highly debated precisely because the
mechanism of lethality is unknown. However, molecular
studies of the brain of autopsy victims who died in states of
excited delirium reveal a loss of dopamine transporter function
as a possible trigger of a lethal cascade of neural activities that
progress to asphyxia and sudden cardiac arrest. Both national
and regional ExDS registries are needed with data about medical
history, toxicology, gender, and race to improve outcomes and
further translational molecular research studies of this highly
disputed and often unrecognized psychopathological condition
associated with central dopamine dysfunction.
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